Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bezlotoxumab - Merck & Co

Next Previous
X
Search
Drug Profile

Bezlotoxumab - Merck & Co

Alternative Names: CDB1; Clostridium difficile toxin B monoclonal antibody; MBL-CDB1; MDX 1388; MK 6072; Zinplava

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medarex; University of Massachusetts Medical School
  • Developer Merck & Co; Merck Sharp & Dohme
  • Class Antidiarrhoeals; Monoclonal antibodies
  • Mechanism of Action Clostridium difficile toxB protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Clostridium difficile infections

Most Recent Events

  • 07 May 2023 Adverse event data from MODIFY I and MODIFY II trials in Clostridium difficile infections presented at the Digestive Disease Week 2023 (DDW-2023)
  • 12 May 2022 Merck Sharp & Dohme completes the phase III MODIFY III trial for Clostridium difficile infections (Adjunctive treatment, In children, In adolescents, In infants) in USA, Argentina, Brazil, Colombia, Czech Republic, Hungary, Germany, Malaysia, Mexico, Norway, Poland, Portugal, Spain, Sweden, Romania, South Africa and United Kingdom (IV) (NCT03182907) (EudraCT2017-000070-11)
  • 20 Jan 2022 Phase III development in Clostridium difficile infections (Adjunctive treatment, In adolescents, In children, In infants) is still ongoing in Czech Republic, Germany, Hungary, Norway, Portugal, Poland, Sweden, Spain, and USA (IV) (NCT03182907)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top